Combination Therapy for EGFR-Mutated Lung Cancer

被引：14

作者：

Wu, Yi-Long ^{[1
]}

Zhou, Qing ^{[1
]}

机构：

[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Acad Med Sci, Guangzhou, Peoples R China

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2023年 / 389卷 / 21期

关键词：

OSIMERTINIB;

D O I：

10.1056/NEJMe2311559

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Targeted therapy has improved prognoses for patients with advanced non-small-cell lung cancer (NSCLC) that has epidermal growth factor receptor (EGFR) mutations. The seminal trial that established precision medicine for EGFR-mutated NSCLC was the Iressa Pan-Asia Study (IPASS),(1) and a second trial, AURA3, showed that resistance mutations could be detected and then targeted with osimertinib.(2) FLAURA was an important third trial that moved osimertinib to the first line of treatment by showing delayed resistance and improved clinical outcomes; progression-free survival was 18.9 months, and overall survival was 38.6 months.(3,4) Osimertinib became the standard therapy for advanced NSCLC with EGFR-sensitive mutations. The story . . .

引用

页码：2005 / 2007

页数：3

共 50 条

[31] Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer [J].

Qureshi, Zaheer ;

Altaf, Faryal ;

Jamil, Abdur ;

Siddique, Rimsha .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01) :44-54

[32] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance [J].

Kai Fu ;

Fachao Xie ;

Fang Wang ;

Liwu Fu .

Journal of Hematology & Oncology, 15

[33] Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer [J].

Di Marino, Pietro ;

Chiapperino, Cosima ;

Primavera, Francesca Chiara ;

Martino, Maria Teresa ;

Brocco, Davide ;

Carella, Consiglia ;

Grassadonia, Antonino ;

Tinari, Nicola ;

De Tursi, Michele .

ONCOTARGETS AND THERAPY, 2022, 15 :407-410

[34] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer [J].

Wang, Huaying ;

Lin, Lie ;

Liang, Chuqiao ;

Pang, Jiaohui ;

Yin, Jiani C. ;

Zhang, Junli ;

Shao, Yang ;

Sun, Chengming ;

Guo, Renhua .

JCO PRECISION ONCOLOGY, 2024, 8

[35] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer [J].

Ferreira, Marion ;

Ebia, Matthew I. ;

Reckamp, Karen L. .

ANTI-CANCER DRUGS, 2024, 35 (07) :672-679

[36] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer [J].

Spagnuolo, Alessia ;

Gridelli, Cesare .

EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (04) :491-501

[37] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis [J].

Huang, Lei ;

Huang, Hao ;

Zhou, Xiao-Ping ;

Liu, Jin-Feng ;

Li, Chun-Rong ;

Fang, Min ;

Wu, Jun-Rong .

MEDICINE, 2019, 98 (43)

[38] Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism [J].

Arai, Sachiko ;

Takeuchi, Shinji ;

Fukuda, Koji ;

Tanimoto, Azusa ;

Nishiyama, Akihiro ;

Konishi, Hiroaki ;

Takagi, Akimitsu ;

Takahashi, Hiroyuki ;

Ong, S. Tong ;

Yano, Seiji .

JOURNAL OF MEDICAL INVESTIGATION, 2020, 67 (3-4) :343-350

[39] Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib [J].

Eggermont, Carolien ;

Gutierrez, Gustavo J. ;

De Greve, Jacques ;

Giron, Philippe .

CANCERS, 2023, 15 (09)

[40] Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer [J].

Arulananda, Surein ;

Do, Hongdo ;

Musafer, Ashan ;

Mitchell, Paul ;

Dobrovic, Alexander ;

John, Thomas .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :1728-1732

← 1 2 3 4 5 →